ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 57,777 shares, a decrease of 40.1% from the June 30th total of 96,526 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily trading volume, of 68,640 shares, the days-to-cover ratio is presently 0.8 days.
Hedge Funds Weigh In On ALPS Medical Breakthroughs ETF
Large investors have recently added to or reduced their stakes in the company. Exencial Wealth Advisors LLC raised its stake in shares of ALPS Medical Breakthroughs ETF by 3.2% in the 4th quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock valued at $415,000 after purchasing an additional 248 shares during the period. Royal Bank of Canada boosted its position in shares of ALPS Medical Breakthroughs ETF by 2.8% during the fourth quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock worth $628,000 after buying an additional 330 shares during the period. Harbor Investment Advisory LLC acquired a new position in shares of ALPS Medical Breakthroughs ETF during the second quarter worth about $29,000. McGuire Investment Group LLC grew its holdings in shares of ALPS Medical Breakthroughs ETF by 5.9% during the fourth quarter. McGuire Investment Group LLC now owns 8,798 shares of the company’s stock worth $451,000 after buying an additional 488 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new position in shares of ALPS Medical Breakthroughs ETF during the fourth quarter worth about $26,000.
ALPS Medical Breakthroughs ETF Trading Up 3.3%
Shares of NYSEARCA:SBIO traded up $2.06 during midday trading on Thursday, reaching $65.20. 17,842 shares of the company were exchanged, compared to its average volume of 37,469. ALPS Medical Breakthroughs ETF has a fifty-two week low of $32.35 and a fifty-two week high of $69.34. The stock has a fifty day simple moving average of $59.23 and a two-hundred day simple moving average of $54.73.
ALPS Medical Breakthroughs ETF Company Profile
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.
See Also
- Five stocks we like better than ALPS Medical Breakthroughs ETF
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for ALPS Medical Breakthroughs ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALPS Medical Breakthroughs ETF and related companies with MarketBeat.com's FREE daily email newsletter.
